Published in Hepatology on May 29, 2014
A Validation Cohort for ACLF Diagnosis and Prognosis (Ch-CANONIC-Val) | NCT03641872
Acute-on-Chronic Liver Failure. Clin Gastroenterol Hepatol (2015) 0.92
Artificial liver support system improves short- and long-term outcomes of patients with HBV-associated acute-on-chronic liver failure: a single-center experience. Medicine (Baltimore) (2014) 0.89
Bacterial infections in cirrhosis: A critical review and practical guidance. World J Hepatol (2016) 0.83
Cirrhotic Multiorgan Syndrome. Dig Dis Sci (2015) 0.82
The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology (2016) 0.82
Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management. World J Gastroenterol (2015) 0.82
Acute-on-chronic liver failure: terminology, mechanisms and management. Nat Rev Gastroenterol Hepatol (2016) 0.82
Hyponatremia and Hepatorenal Syndrome. Gastroenterol Hepatol (N Y) (2015) 0.79
Acute-on-chronic liver failure. Clin Liver Dis (2014) 0.79
Role of systemic inflammation in cirrhosis: From pathogenesis to prognosis. World J Hepatol (2015) 0.77
Characteristics and outcomes of chronic liver disease patients with acute deteriorated liver function by severity of underlying liver disease. World J Gastroenterol (2016) 0.77
Bile duct-ligated mice exhibit multiple phenotypic similarities to acute decompensation patients despite histological differences. Liver Int (2015) 0.77
Characteristics, Diagnosis and Prognosis of Acute-on-Chronic Liver Failure in Cirrhosis Associated to Hepatitis B. Sci Rep (2016) 0.77
Six month abstinence rule for liver transplantation in severe alcoholic liver disease patients. World J Gastroenterol (2015) 0.75
Acute-on-chronic liver failure: a new syndrome in cirrhosis. Clin Mol Hepatol (2016) 0.75
ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for a single-arm feasibility trial. BMJ Open (2016) 0.75
Specific Etiologies Associated With the Multiple Organ Dysfunction Syndrome in Children: Part 2. Pediatr Crit Care Med (2017) 0.75
Population-representative Incidence of Acute-On-Chronic Liver Failure: A Prospective Cross-Sectional Study. J Clin Gastroenterol (2016) 0.75
Acute on Chronic Liver Failure-What is in a 'Definition'? J Clin Exp Hepatol (2016) 0.75
Presepsin teardown - pitfalls of biomarkers in the diagnosis and prognosis of bacterial infection in cirrhosis. World J Gastroenterol (2016) 0.75
Proton pump inhibitor prescription abuse and sepsis in cirrhosis. World J Gastrointest Pharmacol Ther (2016) 0.75
The Clinical Course of Cirrhosis Patients Hospitalized for Acute Hepatic Deterioration: A Prospective Bicentric Study. Medicine (Baltimore) (2015) 0.75
Toward a Better Definition of Acute-on-Chronic Liver Failure. J Clin Exp Hepatol (2017) 0.75
Acute-on-chronic liver failure: an update. Gut (2017) 0.75
Chronic liver failure-consortium acute-on-chronic liver failure and acute decompensation scores predict mortality in Brazilian cirrhotic patients. World J Gastroenterol (2017) 0.75
Gender-Specific Differences in Baseline, Peak, and Delta Serum Creatinine: The NACSELD Experience. Dig Dis Sci (2016) 0.75
Liver Transplantation for Acute on Chronic Liver Failure. J Clin Exp Hepatol (2017) 0.75
Ascites, refractory ascites and hyponatremia in cirrhosis. Gastroenterol Rep (Oxf) (2017) 0.75
APACHE II: a severity of disease classification system. Crit Care Med (1985) 69.83
Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology (2013) 5.88
Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol (2013) 4.24
Acute-on chronic liver failure. J Hepatol (2012) 3.74
Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology (2010) 3.00
Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis (2008) 2.47
Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology (2013) 2.33
Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology (2012) 1.92
Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology (2012) 1.74
Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol (2011) 1.61
Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol (2010) 1.36
New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology (2013) 1.35
Patients with cirrhosis and denied liver transplants rarely receive adequate palliative care or appropriate management. Clin Gastroenterol Hepatol (2013) 1.16
High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center. Clin Gastroenterol Hepatol (2012) 1.15
Defining acute-on-chronic liver failure: will East and West ever meet? Gastroenterology (2013) 1.12
Bacterial infections in end-stage liver disease: current challenges and future directions. Gut (2012) 1.00
Factors that predict short-term intensive care unit mortality in patients with cirrhosis. Clin Gastroenterol Hepatol (2013) 0.88
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol (2002) 8.21
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med (2008) 6.67
Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med (2005) 6.31
Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol (2005) 6.22
Vascular disorders of the liver. Hepatology (2009) 5.38
Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med (2013) 5.19
Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology (2010) 5.00
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut (2007) 4.51
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology (2007) 4.09
The Budd-Chiari syndrome. N Engl J Med (2004) 3.95
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92
Acute-on chronic liver failure. J Hepatol (2012) 3.74
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology (2002) 3.50
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology (2004) 3.47
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med (2009) 3.41
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. J Clin Invest (2007) 3.22
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
Bacterial translocation (BT) in cirrhosis. Hepatology (2005) 3.07
The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology (2003) 3.00
MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology (2005) 2.99
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91
A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology (2008) 2.69
Clinical risk factors for portopulmonary hypertension. Hepatology (2008) 2.62
Splanchnic artery aneurysms. Mayo Clin Proc (2007) 2.55
Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis (2008) 2.47
First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat (2002) 2.43
Improvement in oncology practice performance through voluntary participation in the Quality Oncology Practice Initiative. J Clin Oncol (2008) 2.39
The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol (2011) 2.37
Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology (2007) 2.36
Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine (Baltimore) (2006) 2.34
Pulmonary vascular complications of liver disease. Am J Respir Crit Care Med (2012) 2.33
Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int (2010) 2.32
Acute kidney injury in decompensated cirrhosis. Gut (2012) 2.29
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology (2014) 2.28
Current epidemiology of hepatitis E virus infection in the United States: low seroprevalence in the National Health and Nutrition Evaluation Survey. Hepatology (2014) 2.27
Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology (2008) 2.26
Hip pain and heart failure: the missing link. Can J Cardiol (2013) 2.26
Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology (2006) 2.25
Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol (2011) 2.23
Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol (2009) 2.22
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology (2004) 2.17
Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol (2010) 2.16
Cost-effectiveness of screening for hepatopulmonary syndrome in liver transplant candidates. Liver Transpl (2007) 2.13
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med (2015) 2.13
Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int (2008) 2.10
Mesenteric venous thrombosis. Mayo Clin Proc (2013) 2.09
A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology (2005) 2.08
Sublingual tissue perfusion improves during emergency treatment of acute decompensated heart failure. Am J Emerg Med (2011) 2.08
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology (2010) 2.06
Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology (2006) 2.05
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (2014) 2.04
A prospective evaluation of computerized tomographic (CT) scanning as a screening modality for esophageal varices. Hepatology (2008) 2.02
Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology (2012) 2.01
Coagulopathy in cirrhosis - the role of the platelet in hemostasis. J Hepatol (2013) 2.01
Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet (2004) 1.96
Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl (2004) 1.95
Performance standards for therapeutic abdominal paracentesis. Hepatology (2004) 1.93
The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology (2013) 1.92
Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology (2012) 1.89
Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology (2014) 1.89
Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl (2005) 1.87
Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements. Am J Transplant (2004) 1.87
The North American Study for the Treatment of Refractory Ascites. Gastroenterology (2003) 1.87
Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. Liver Transpl (2007) 1.86
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol (2004) 1.83
Transjugular intrahepatic portosystemic shunts: an update. Liver Transpl (2003) 1.83
Hepatocellular carcinoma after the Fontan procedure. N Engl J Med (2013) 1.81
Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf (2011) 1.76
Recommendations for probiotic use--2008. J Clin Gastroenterol (2008) 1.76
Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology (2012) 1.74
Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl (2006) 1.72
Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl (2008) 1.72
Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology (2006) 1.71
Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology (2008) 1.70